

DRUG PRIOR AUTHORIZATION COMMITTEE
September 19, 2013
TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15- 11:15	Pharmacy Program/ Budget Update	Rhonda Driver/ Andrew Haslag
11:15 - 11:20	DUR Update	Rhonda Driver

Old Business

11:20 – 11:30	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
---------------	--	---------------

New Business

11:30 – 11:45	B. Proposed Actions- New Drug/Product Reviews (See website and Attached Summary) i. Open Access ii. Clinical Edit/Step Therapy iii. PDL Products iv. Prior Authorization <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Rhonda Driver
---------------	---	---------------

11:45 – 1:00	C. <u>Clinical Edits</u> i. Familial Hypercholesterolemia Inhibitors Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision ii. SGT-2 Inhibitors Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision iii. Narcolepsy Inhibitors Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
--------------	--	--

D. Preferred Drug List (PDL)

- I. **ACE Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- II. **ACE Inhibitor Diuretic Combinations**
 - Discussion
 - Public Hearing
 - Decision
- III. **ACE Inhibitor/Calcium Channel Blocker**
 - Discussion
 - Public Hearing
 - Decision
- IV. **Angiotensin Receptor Blocker**
 - Discussion
 - Public Hearing
 - Decision
- V. **Angiotensin Receptor Blocker Diuretic Combinations**
 - Discussion
 - Public Hearing
 - Decision
- VI. **Anticoagulant Agents**
 - Discussion
 - Public Hearing
 - Decision
- VII. **Beta Adrenergic Blockers and Diuretic Combinations**
 - Discussion
 - Public Hearing
 - Decision
- VIII. **Calcium Channel Blockers: Dihydropyridine**
 - Discussion
 - Public Hearing
 - Decision
- IX. **Calcium Channel Blockers: Non- Dihydropyridine**
 - Discussion
 - Public Hearing
 - Decision
- X. **ARB/CCB Combination Agents**
 - Discussion
 - Public Hearing
 - Decision
- XI. **Direct Renin Inhibitor & Combinations**
 - Discussion
 - Public Hearing
 - Decision

- XII. Lipotropics – Niacin Preparations & Combinations**
 - Discussion
 - Public Hearing
 - Decision
- XIII. Lipotropics - Statins**
 - Discussion
 - Public Hearing
 - Decision
- XIV. Proton Pump Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- XV. Pulmonary Hypertension Agents – Inhaled/Injectable**
 - Discussion
 - Public Hearing
 - Decision
- XVI. Pulmonary Hypertension Agents - Oral**
 - Discussion
 - Public Hearing
 - Decision
- XVII. Triglyceride Lowering Agents**
 - Discussion
 - Public Hearing
 - Decision

E. Preferred Drug List

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

LUNCH

1:15-1:30

Program Utilization Information-Xerox Update

Rhonda Driver/
Jennifer Kemp-Cornelius

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

Executive Session

1:50-1:55

Minutes Review Discussion/Approval

1:55-2:30

Case Reviews Jenna Twehus

NEXT MEETING: Decembe 19, 2013